PALATIN TECHNOLOGIES INC (PTN)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Palatin Technologies, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 17, 2026 | 6.06 | 6.15 | 5.25 | 5.36 | 53,805 |
| Nov 16, 2026 | 6.27 | 6.27 | 6.02 | 6.13 | 18,867 |
| Nov 13, 2026 | 6.38 | 6.39 | 5.81 | 6.23 | 30,204 |
| Nov 12, 2026 | 6.58 | 6.67 | 6.17 | 6.57 | 13,487 |
| Nov 11, 2026 | 7.17 | 7.17 | 6.73 | 6.86 | 12,000 |
| Nov 10, 2026 | 6.89 | 7.15 | 6.70 | 6.89 | 25,217 |
| Nov 9, 2026 | 6.69 | 7.33 | 6.23 | 7.23 | 156,596 |
| Nov 6, 2026 | 5.93 | 6.62 | 5.67 | 6.27 | 33,994 |
| Nov 5, 2026 | 6.02 | 6.04 | 4.76 | 5.71 | 57,180 |
| Nov 4, 2026 | 5.36 | 6.20 | 5.24 | 6.02 | 51,426 |
| Nov 3, 2026 | 5.05 | 5.68 | 5.05 | 5.22 | 22,355 |
| Nov 2, 2026 | 5.12 | 5.31 | 4.83 | 4.99 | 30,715 |
| Oct 30, 2026 | 4.93 | 5.11 | 4.89 | 5.00 | 16,039 |
| Oct 29, 2026 | 4.97 | 5.30 | 4.74 | 4.93 | 12,214 |
| Oct 28, 2026 | 4.65 | 5.17 | 4.51 | 5.10 | 42,460 |
| Oct 27, 2026 | 4.93 | 5.02 | 4.70 | 4.77 | 33,292 |
| Oct 26, 2026 | 5.10 | 5.42 | 4.58 | 4.82 | 28,085 |
| Oct 23, 2026 | 5.44 | 5.89 | 4.92 | 5.11 | 126,577 |
| Oct 22, 2026 | 5.75 | 5.78 | 5.50 | 5.51 | 13,649 |
| Oct 21, 2026 | 5.60 | 5.85 | 5.40 | 5.55 | 20,481 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Director | Withholding/Transfer | 2.9K | -- | Aug 3, 2026 | |
| Director | Withholding/Transfer | 2.4K | -- | Aug 3, 2026 | |
| Director | Withholding/Transfer | 2.2K | -- | Aug 3, 2026 | |
| President and CEO | Automatic Sell | 119 | $1.4K | Jul 15, 2026 | |
| President and CEO | Automatic Sell | 33 | $388.41 | Jul 15, 2026 | |
| Executive VP and CFO/COO | Automatic Sell | 94 | $1.3K | Jul 15, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Logos Global Management LP · also on 13F· joint filing· may incl. warrants· filed May 2026 | 182.2K | 10.2% | 13G |
JANUS HENDERSON GROUP PLC · also on 13F· may incl. warrants· filed Dec 2025 | 170.1K | 9.6% | 13G |
Driehaus Capital Management LLC | 166.7K | 9.4% | 13F |
Janus Henderson Group Ltd. | 140.0K | 7.9% | 13F |
Jupiter Topco LLC | 140.0K | 7.9% | 13F |
DEVEER ROBERT K JR Director | 138.1K | 7.8% | FORM 4 |
Ikarian Capital, LLC | 130.0K | 7.3% | 13F |
Logos Global Management LP | 129.3K | 7.3% | 13F |
Ikarian Capital, LLC · also on 13F· joint filing· may incl. warrants· filed Nov 2026 | 123.1K | 6.9% | 13G |
SPANA CARL President and CEO, Director | 64.9K | 3.6% | FORM 4 |
Insiders
- PRENDERGAST JOHN K ADirector
- Morris ArleneDirector
- DUNTON ALAN WDirector
- SPANA CARLPresident and CEO
- WILLS STEPHEN TExecutive VP and CFO/COO
- DEVEER ROBERT K JRDirector
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States.
The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.
It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases.
In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis.
The company was incorporated in 1986 and is based in Cranbury, New Jersey.
based on 1.78M shares outstanding
30d Avg
41.80K
60d Avg
35.83K
90d Avg
72.66K
Signal8's dilution snapshot of PTN as of Sep 30, 2026 records an at-the-market sales agreement dated Feb 11, 2025, 17 outstanding warrant series and a public offering closed Nov 12, 2025, from SEC filings. Palatin Technologies Inc. (NASDAQ: PTN) traded at $5.36 on Nov 17, 2026, down 12.49% from the previous close of $6.13. 52-week range: $4.51 to $31.00. The company is in the Healthcare sector (Biotechnology).